For the twelve months ended Jun 30, 2026, Sanara MedTech Inc. reported $109.81M of revenue and -$32.02M of net income.
SMTI revenueQ2 2026$28.14M
- Quarter YoY
- +9.0%
- QoQ
- +1.2%
- FY YoY
- +19.0%
- 5Y CAGR
- +45.9%
- 10Y CAGR
- +40.8%
SMTI revenue was $28.14M in fiscal Q2 2026 (ended Jun 30, 2026), up 9.0% from a year earlier and up 1.2% from the prior quarter. For the full fiscal 2025 it was $103.12M, up 19.0% from fiscal 2024. Compound annual growth was +45.9% over 5 years and +40.8% over 10 years. It rose in 9 of the last 10 fiscal years. Fiscal 2025 is the highest of the 15 fiscal years on file.
SMTI net incomeQ2 2026-$452.9K
SMTI net income was -$452.9K in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$2.01M a year earlier. For the full fiscal 2025 it was -$37.56M, compared with -$9.66M in fiscal 2024.
SMTI EPSQ2 2026-$0.05
SMTI diluted EPS was -$0.05 in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$0.23 a year earlier. For the full fiscal 2025 it was -$4.36, compared with -$1.14 in fiscal 2024.
SMTI free cash flowQ2 2026$2.03M
- Quarter YoY
- +125.2%
SMTI free cash flow was $2.03M in fiscal Q2 2026 (ended Jun 30, 2026), up 125.2% from a year earlier. For the full fiscal 2025 it was $2.16M, compared with -$229.6K in fiscal 2024. Fiscal 2025 is the highest of the 13 fiscal years on file.
Source: XBRL data Sanara MedTech Inc. files with the SEC, latest filing dated Aug 11, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.